In high-grade serous ovarian cancers, due to the silencing of PML, ROS content, lipid peroxidation, and lysosomes, and the lysosomal Fe2+levels are reduced, which can result in potential ferroptosis and improved sensitivity to immunotherapy (Gentric et al., 2019). This evidence concerns the gene PML and ovarian serous adenocarcinoma.